# Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

> **NCT02792517** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 41 (actual)

## Conditions studied

- Headache, Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Ethynil Estradiol/Norgestimate Oral Contraceptive

## Key facts

- **NCT ID:** NCT02792517
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-12
- **Primary completion:** 2016-09-09
- **Final completion:** 2016-09-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02792517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02792517, "Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02792517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*